Skip to main content

DIAN-TU

All trials

Alzheimer

DIAN-TU

Leeftijd icoon
18 - 80 years (M / F)
Diagnose icoon
Genetic variant of Alzheimer's disease
Duratie onderzoek
Duration of the CRI period depends on when a decision was made about the research drug to be tested
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

Cognitive Run In period (CRI period – Cognitive Run In period)

The aim of this study is to enable the researchers to start collecting and studying data (information) from participants in the study. This includes personal information, how the disease occurs in your family, your cognitive functions and biomarkers and the changes in these. This gives the researchers an idea of the course of the disease per participant without medication and offers participants the opportunity to become familiar with what participation in the clinical trial entails.

The CRI period takes place prior to the start of the actual research with treatment groups. You will not be given any research drug in the CRI examination.

The duration of the investigation of the CRI period depends on when a decision has been made which investigational agent will be tested.

This study is commissioned by Washington University.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening and visits

During the screening period, it is determined within 8 weeks whether you meet the research criteria and also whether your health allows participation in the research. If so, you can participate in the study.

Then a “baseline measurement” is taken. This includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, and a PET scan.

Thereafter, study visits take place approximately every 12 weeks for the remainder of the study. Depending on the procedure and the type of study visit, procedures may be performed at your home or at the Brain research center, and their length may vary.

Extensive examinations take place every year in which information is collected about your health with physical and neurological examinations, an ECG (heart film), memory tests, questionnaires, an MRI, and a PET scan. These appointments can be spread over 2 days. Participation is voluntary at all times.

Who can participate?

  • There is a genetic variant of Alzheimer’s disease in your family
    • And know that you yourself are a mutation carrier
    • And you don’t know and don’t want to know
  • You are between 18 and 80 years old
  • You do not yet have symptoms consistent with Alzheimer’s disease
  • Or you already have symptoms (maximum 10 years),
    • In this case, the possible use of Alzheimer’s medication is allowed
  • You have a family carer who can accompany you during a few visits to the research center and answer questions about your health and functioning, among other things.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

Alnylam

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle